Morris Nechama

1.0k citations
22 papers · 522 indexed · h-index 15
Topics
Parathyroid Disorders and Treatments (6 papers)Signaling Pathways in Disease (6 papers)Renal and related cancers (4 papers)
Partner nations
IsraelUnited StatesChina

In The Last Decade

Morris Nechama

21 papers receiving 520 citations

Peers

Morris Nechama
Comparison fields: 5 of 72
  • Molecular Biology 306
  • Nephrology 127
  • Immunology 124
  • Oncology 93
  • Genetics 82
Replace Asta Valančiūtė with:
Asta Valančiūtė France
Minoru Nakazato Japan
Kristian B. Laursen United States
Eva María Blanco Spain
J Turner United Kingdom
Stefanie Tippmer Germany
Pamela Farfán Chile
Chiara Verdelli Italy
Taku Fukuzawa Japan
Xiaoyang Wan China
Morris Nechama relative to Asta Valančiūtė France Asta Valančiūtė's profile →
Citations per field
00.5×1.7×
Asta Valančiūtė · 1×
Citations per year

Countries citing papers authored by Morris Nechama

Since Specialization
Citations

This map shows the geographic impact of Morris Nechama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Morris Nechama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Morris Nechama more than expected).

Fields of papers citing papers by Morris Nechama

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Morris Nechama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Morris Nechama. The network helps show where Morris Nechama may publish in the future.

Co-authorship network of co-authors of Morris Nechama

This figure shows the co-authorship network connecting the top 25 collaborators of Morris Nechama. A scholar is included among the top collaborators of Morris Nechama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Morris Nechama. Morris Nechama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 1
3 3
4 3
5 11
6 7
7 66
8 24
9 27
10 76
11 33
12 17
13 18
14 14
15 65
16 22
17 44
18 14
19 40
20 5

About Morris Nechama

Morris Nechama is a scholar working on Nephrology, Molecular Biology and Physiology, having authored 22 papers that have together received 522 indexed citations. Recurring topics across this work include Parathyroid Disorders and Treatments (6 papers), Signaling Pathways in Disease (6 papers) and Renal and related cancers (4 papers). The work is most often cited by research in Nephrology (127 citations), Immunology (124 citations) and Molecular Biology (306 citations). Morris Nechama has collaborated with scholars based in Israel, United States and China. Frequent co-authors include Tally Naveh‐Many, Justin Silver, Iddo Z. Ben‐Dov, Takafumi Uchida, Kun Ping Lu, Paola Briata, Roberto Gherzi, Xiao Zhen Zhou, Mohamed S. Arredouani and Vitali Shilo. Their work appears in journals such as Journal of Clinical Investigation, Nature Communications and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026